51. 全身性強皮症 Scleroderma Clinical trials / Disease details


臨床試験数 : 523 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03388255
(ClinicalTrials.gov)
November 8, 201621/12/2017Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma DiseasesA Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma DiseasesScleroderma DiseaseDrug: PolydeoxyribonucleotidesMastelli S.r.lSintesi Research SrlTerminated18 YearsN/AAll25Phase 4Italy
2EUCTR2015-005100-28-IT
(EUCTR)
18/07/201617/01/2022A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in patients with cutaneous lesions in scleroderma diseases.A phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in scleroderma diseases. - A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in p Fibrotic and atrophic cutaneous lesions in localized scleroderma diseases.
MedDRA version: 20.0;Level: HLT;Classification code 10039711;Term: Scleroderma and associated disorders;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿
Product Name: PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml
INN or Proposed INN: POLYDEOXYRIBONUCLEOTIDES
Other descriptive name: PLACENTEX ® Polydeoxyribonucleotide
MASTELLI SRLNULLNot RecruitingFemale: yes
Male: yes
45Phase 4Italy